S&P Futures
4,015.25 +8.00 (+0.20%) Dow Futures
32,685.00 +54.00 (+0.17%) Nasdaq Futures
12,823.00 +34.50 (+0.27%) Russell 2000 Futures
1,772.40 +5.10 (+0.29%) Crude Oil
73.00 +0.19 (+0.26%) Gold
1,959.20 +5.40 (+0.28%)
Sino Biopharmaceutical Limited (SMZ1.SG)
Chart Events
Performance Outlook
| Previous Close | 0.5002 |
| Open | 0.5088 |
| Bid | 0.5112 x 1111100 |
| Ask | 0.5312 x 1111100 |
| Day's Range | 0.5088 - 0.5096 |
| 52 Week Range | 0.4411 - 0.6496 |
| Volume | |
| Avg. Volume | 1,701 |
| Market Cap | 4.102B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 15.44 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SMZ1.SG
Related Research
- GlobeNewswire
invoX Pharma and F-star Therapeutics issue Joint Statement
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report: The parties continue working together in active discussions with the Committee on Foreign Investment in the United States (“CFIUS”) about the terms of a mitigation agreement to add
- Reuters
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots. The decline from 2.06 billion yuan ($299.8 million) to 629.8 million yuan was mainly driven by weaker COVID vaccine demand as growth in global uptake slowed and price changes of CanSinoBIO's products, the firm said in a company filing published on Sunday. CanSinoBIO, which sells a one-dose shot in countries including China and Mexico and is seeking approval for an inhaled version of the vaccine, said half-year net profit dropped by 98.7% year-on-year.
- Zacks
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
